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Role of the Capsid Helix 4-5 Loop in Equine Infectious Anemia Virus Infection 
 
Abstract 
 
The lentiviral capsid core, which encapsulates the viral RNA genome, is delivered 
into the target cell cytoplasm during the viral entry process.  In the cytoplasm, the conical 
core undergoes morphological changes, which are termed uncoating.  Proper uncoating 
has been shown to be critical for the infectivity of the lentivirus HIV-1.  In addition, the 
HIV-1 capsid protein is critical for the process of nuclear import of the preintegration 
complex (PIC).  The lentivirus equine infectious anemia virus (EIAV) shares many 
similarities to HIV-1, including similarities in the capsid protein.  In particular, both HIV-
1 and EIAV capsid contain a proline-rich loop region in the amino terminal domain of 
capsid between helices 4 and 5.  The host cellular factor cyclophilin A binds this loop in 
HIV-1 and is critical for proper uncoating.  We hypothesized that this helix 4-5 loop was 
also critical for EIAV infectivity at some early step in the viral infection cycle.  We 
created a panel of amino acid substitution mutations in this loop region.  Some of the 
mutations resulted in severely deleterious effects on EIAV infectivity.  Some mutations 
caused a slight increase in infectivity.  The deleterious mutations did not affect uncoating 
or reverse transcription but appeared to block nuclear import of the PIC.  Those 
mutations in which infectivity was slightly increased did not exhibit significantly 
different phenotypes from wild-type EIAV at any of the stages examined.  The results of 
this study lend further support to the role of capsid as a determinant of nuclear import and 
suggest that viral and cellular factors critical to HIV-1 import may also be applicable to   iv
EIAV.  Future research should focus on identifying the causes of the defects in nuclear 
import observed for some mutants, as well as attempt to identify the reason for the 
infectivity increase in others.  In addition, inclusion of EIAV in future studies of nuclear 
import involving HIV-1 can broaden the scope of the data to lentiviruses in general rather 
than HIV-1 in particular.    v
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CHAPTER 1 
 
INTRODUCTION  
 
 
2
The Retroviridae family consists of a large group of viruses that undergo an unusual step during 
their infection cycle, from which they derive their name.  Virions contain an RNA genome, but 
during infection this RNA is copied into DNA:  a process termed reverse transcription.  This 
flow of genetic material is in the opposite direction of that termed the central dogma (DNA → 
RNA → protein).  The “retro” part of the family name derives from this step.  After reverse 
transcription, the viral DNA is integrated into the host genome.  This DNA is then transcribed 
and translated normally, giving rise to the viral proteins and also the RNA genome that will be 
packaged into progeny virions.  The integration of the viral DNA into the host’s genome allows 
retroviruses to maintain a persistent infection, as their integrated DNA is replicated along with 
the  host’s  by  the  cellular  replication  machinery.    The  reverse  transcription  process  and 
subsequent integration step are the defining life cycle features that distinguish the Retroviridae 
from other viruses. 
All retroviruses share a basic structure when visualized by electron microscopy.  There is 
an internal electron-dense complex, or core, whose shape varies between retroviral genera.  But 
for all types of retrovirus, this core is surrounded by a lipid bilayer membrane, from which 
envelope glycoproteins protrude as spikes on the virion surface [for review, (67)].  There are 
seven genera of Retroviridae.  These seven fall into two categories, simple and complex, and this 
division is based on the viral genome.  Simple retroviruses encode only four genes (which may 
be thought of as the “minimal” genes required for replication).  These genes are gag, pol, pro, 
and  env.    They  may  share  reading  frames  or  be  expressed  in  separate  ORFs.    Complex 
retroviruses encode the four genes mentioned above as well as accessory genes with diverse 
functions.  The simple retroviruses are alpha-, beta-, and gammaretroviruses.  Alpharetroviruses  
 
 
3
contain a  centrally-placed spherical core (example:  avian leukemia virus).   Betaretroviruses 
contain a core which is either cylindrical or round and is eccentrically placed within the virion 
sphere  (examples:    mouse  mammary  tumor  virus,  Mason-Pfizer  monkey  virus).  
Gammaretroviruses also contain a central spherical core (example:  leukemia viruses, e.g. murine 
and  feline).    Complex  retroviruses  are  delta-,  epsilon-,  lenti-  and  spumaviruses.    The 
deltaretroviruses contain a spherical core and accessory genes tax and rex (example:  human T-
lymphotropic  viruses  [HTLVs]).    Epsilonretroviruses  also  have  a  spherical  core  and  1-3 
additional open reading frames (A, B, C).  The only examples of this type of retrovirus are found 
in fish (e.g. wall-eye dermal sarcoma virus) and reptiles.  The lentiviruses have unique core 
morphology  –  the  core  complex  from  immature  virions  is  spherical,  but  upon  maturation  it 
becomes  cone-shaped  or  cylindrical.    Lentiviruses  also  express  several  accessory  genes.  
Examples  are  vif,  vpu,  vpr,  tat,  rev  and  nef  from  HIV-1,  and  tat,  rev  and  S2  from  equine 
infectious  anemia  virus  (EIAV).    Finally,  spumaviruses  contain  a  central,  uncondensed  core 
which does not exhibit morphology changes upon maturation (example:  human foamy virus).  
Spumaviruses encode two accessory genes, bel-1 and bet.  [For review (45, 54-56, 67, 191)] 
Although  the  different  genera  of  Retroviridae  exhibit  varying  core  morphology  and 
accessory genes, all encode the same four basic genes and therefore show a similar overall virion 
structure.  Gag encodes the structural proteins capsid (CA), matrix (MA), nucleocapsid (NC) and 
proteins of various sizes typically containing “late domains”.  All retroviruses have an RNA 
genome, which is enclosed in the core complex and is itself associated with NC [for review 
(67)].  Surrounding the RNA/NC complex is the core complex, which is composed mostly of CA 
(86, 111, 143, 171, 197).  This core is surrounded by MA, which is in turn surrounded by the 
lipid bilayer membrane derived from the host cell (11, 96, 172).  Within the lipid bilayer are the  
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protein products of env:  the envelope glycoproteins surface unit (SU) and transmembrane (TM).  
TM passes through the  lipid bilayer and anchors SU on the virion surface (57, 181).   Also 
located  within  the  core  complex  are  those  proteins  derived  from  pol  and  pro:    reverse 
transcriptase (RT), integrase (IN) and protease (PR) (113, 163). 
Retroviruses go through a complex series of steps during their infection cycles.  Though 
some details may differ, overall the steps are the same for all Retroviridae.  They are divided into 
two parts:  early and late stages.  The early stage describes the part of the life cycle between the 
virion and provirus, and the late stage describes the part of the cycle between provirus  and 
infectious virion.  The life cycle steps are briefly summarized below. 
Entry:  receptor binding/membrane fusion.  All retroviruses require that the viral envelope 
glycoprotein  trimer  interact  with  one  or  more  cell  surface  molecules,  which  are  known  as 
receptors.    This  binding  leads  to  conformational  changes  within  the  envelope  glycoprotein 
complex,  which  brings  viral  and  target  cell  lipid  membranes  closer  together  and  allows 
membrane fusion.  Upon fusion, the virion core complex is internalized into the cell cytoplasm. 
[For review (16, 38, 155, 203)] 
Uncoating.  The term “uncoating” refers to events that happen after the viral core has entered the 
cytoplasm, prior to reverse transcription.  These events are still poorly understood.  During this 
stage, it is expected that the viral core will disassemble to some degree.  However, it is still not 
clear whether reverse transcription of the RNA genome requires specific disassembly events to 
happen before it can initiate.  Viruses defective in this step may manifest defects in creating 
reverse transcripts.  Many mutations that appear to interfere with uncoating map to the viral 
capsid protein. [For review (9, 161, 206)]  
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Reverse transcription.  The viral RNA genome is converted to double-stranded DNA at this step, 
which takes place shortly after the core complex enters the cytoplasm.  Reverse transcription 
itself takes place within a large complex that contains the RNA, reverse transcriptase, NC, IN 
and possibly CA (19).  Although reverse transcription appears to be contingent upon the viral 
core being exposed to high levels of dNTPs in the cytoplasm, some viruses may initiate it much 
earlier,  during  assembly  or  release  of  the  particle  (141,  156,  208,  218,  219,  227).    Reverse 
transcription follows an order of discrete steps:  formation of minus-strand strong-stop DNA, 
first translocation, long minus-strand synthesis, initiation of plus-strand synthesis, removal of the 
tRNA primer, second translocation, and completion of both strands. [For review (10, 45, 83)] 
Integration.  The product of reverse transcription is a full-length double-stranded linear DNA 
complex,  flanked  at  each  end  by  long  terminal  repeat  sequences  (LTRs).    After  reverse 
transcription, this complex enters the nucleus.  The actual integration of viral DNA is mediated 
by IN.  IN processes the DNA ends and then catalyzes a strand transfer reaction in which the 
recessed ends make breaks in the target host DNA (183).  The resulting intermediate is repaired 
by cellular DNA repair machinery.  The protein complex involved in integration of the provirus 
is called the pre-integration complex (PIC).  Viral proteins associated with the PIC may include 
CA, RT, IN, MA and NC. [For review (61, 135, 167, 211)] 
Expression of viral RNAs, translation and protein processing.  The integration of the viral 
DNA marks the end of the early stage of infection.  The late phase begins with the synthesis of 
viral RNAs.  The first product is a long primary transcript.  This transcript may be spliced to 
form a number of subgenomic transcripts that will be translated into protein, or it may remain 
unspliced; the unspliced transcript can be translated or may be packaged as the RNA genome of  
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progeny virus. [For review (5, 43, 95, 117, 154)]  The gag, pol, and pro genes are translated as 
long polyprotein precursors (e.g. HIV-1 Gag precursor Pr55).  These polyproteins are processed 
by protease (PR) during or after assembly to form the mature virion particle (e.g. Gag Pr55 → 
MA, CA, NC and p6).  In all retroviruses, env is expressed from a subgenomic mRNA, but gag, 
pol and pro  gene  arrangement differs. Pro may  be fused in-frame to  the end of gag or the 
beginning of pol, or it may have its own ORF.  In addition, gag and pol may be in the same ORF 
(epsilon-,  gammaretroviruses)  or  may  be  in  different  ORFs  and  require  a  frameshift  during 
translation (alpharetro-, lentiviruses).  In addition, the complex retroviruses express a number of 
small accessory proteins translated from subgenomic mRNAs.  [For review (31, 68, 85, 90, 91, 
103, 213)] 
Virion assembly/RNA packaging.  As viral proteins are synthesized, they begin to assemble to 
form the immature particle.  This process is mainly driven by the uncleaved Gag precursor.  
Assembly may occur either at the plasma membrane or in the cytoplasm followed by subsequent 
transfer  to  the  plasma  membrane.    Proteins  derived  from  pol  and  env  as  well  as  accessory 
proteins are incorporated into the assembling virion through contacts with the Gag polyprotein.  
In  addition,  the  envelope  glycoprotein  spikes  are  concentrated  at  the  sites  from  which  the 
particles will bud.  Some host proteins may also get packaged into particles, such as cytoskeletal 
proteins  or  various  host  factors  (e.g.  HIV-1  and  cyclophilin  A).    The  RNA  genome  is 
incorporated via the interaction of specific nucleotide sequences in the RNA (Psi ψ sequences) 
with the nucleocapsid (NC) region of the Gag polyprotein.  [For review of assembly, (1, 79, 85, 
149). For review of RNA packaging, (17, 108, 178)]  
 
 
7
Protein processing/virion maturation.  Upon budding, the precursor proteins must be cleaved to 
give rise to a mature particle.  This cleavage is carried out by PR, which first cleaves itself out of 
its precursor and then cleaves the other polyproteins.  The Gag precursor is cleaved into MA, 
which forms a shell within the inner face of the membrane; CA, which condenses to form the 
distinctively-shaped virion core; NC, which coats the RNA genome; and, in lentiviruses, a fourth 
protein which may vary in size (e.g. HIV-1 and p6, EIAV and p9).  The Pol precursor is cleaved 
to yield RT and IN, and the Env precursor to SU and TM subunits.  The morphological change 
from an immature particle (spherical core with an electron-lucent center) to a mature particle 
(condensed electron-dense core structure with a distinctive shape) is particularly reliant upon the 
processing  of  the  Gag  polyprotein.    Upon  maturation,  the  virion  is  ready  to  re-initiate  the 
infection cycle.  [For review:  (2, 14, 29, 51, 85, 148, 179)]   
Due to their integration into the host genome, retroviruses are not easily eliminated by the 
host’s  immune  system.    The  host  remains  infected  for  life  and  may  have  chronic  low-level 
viremia.  The effects of retroviral infection vary widely by virus.  Since the provirus inserts into 
the host genome, each insertion event represents a mutation.  Over time, accumulation of these 
mutations  can  affect  genes  involved  in  cell  growth  and  division,  resulting  in  abnormal  cell 
proliferation.  Many of the simple retroviruses cause disease in this manner, leading to tumor 
formation or what are termed “slow” leukemias [for examples, see (47, 63)].  In addition, some 
retroviruses may encode genes that cause rapid tumor formation, which they have picked up via 
recombination events with the host genome.  These genes are then expressed at high levels in the 
infected cell.  This type of retrovirus is called an acute transforming virus due to its ability to 
rapidly transform cells and initiate tumorigenesis (189, 202).  Finally, there are retroviruses that 
are directly cytopathic.  This group includes many of the better-known complex retroviruses,  
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including those which infect humans, such as the lentivirus HIV-1.  Aside from replication-
competent  retroviruses  and  acute  transforming  retroviruses,  all  cells  contain  retrovirus-like 
elements  integrated  into  the  host  genome,  termed  endogenous  retroviral  elements.    These 
elements have accumulated over time, cannot be removed, are rarely lost, and are usually heavily 
methylated and not transcribed.  In addition, the endogenous retroviral DNA sequence is usually 
not capable of encoding proteins due to numerous stop codons and frameshifts within ORFs.  
[For review (142, 169)]  In addition, some of these retroelements can transpose intracellularly.  
Such a transposition event essentially creates a “new” provirus, insertion of which constitutes a 
new mutation within the host’s genome. [For review (54, 55)] 
The study of the retrovirus life cycle has led to the development of retroviruses and 
retroviral-based vectors as gene transfer tools.  Particles can be generated in a packaging cell line 
that includes gag, pol and env genes but which packages the gene to be transferred rather than 
the viral RNA genome (6, 38, 46, 144-146).  The resulting virus infects cells and the transferred 
gene integrates into the host genome.  Because retroviral particles can easily be pseudotyped 
with the envelope proteins of other viruses, it is easy to target these recombinant viruses to a 
specific cell type or multiple cell types (60, 193, 214).  Integration into the host’s DNA ensures 
that the gene of interest will not be lost upon cell division. 
Lentiviruses 
The best-known retroviruses are those that cause disease in humans, particularly the lentivirus 
HIV-1.  Although lentiviruses share the same basic infection cycle, genes, proteins and virion 
morphology as other retroviruses, there are some important differences particular to this genus.  
The most observable difference involves core morphology:  although lentiviruses have spherical  
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cores upon budding, the mature virion has a cone-shaped core (23, 32, 59, 157).  In addition, 
lentiviruses commonly encode the regulatory proteins Tat and Rev in addition to the typical 
proteins encoded by gag, pol, pro and env.  Tat (Transactivator of transcription) is involved in 
driving transcription from the LTR.  Basal levels of transcription are usually low.  Tat interacts 
with the LTR via a sequence region called the transactivation response element (TAR).  Tat then 
recruits  various  transcriptional  complexes  to  the  LTR,  such  as  the  positive  transcription 
elongation  factor  b  (pTEFb)  complex;  this  increases  the  elongation  activity  of  the  RNA 
polymerase II complex.  [For review (42, 71, 115, 184, 185)]   
The Rev protein is involved in the translocation of unspliced or partially-spliced mRNA 
from the nucleus to the cytoplasm for translation or virion encapsidation.  Lentiviral genomes are 
relatively small, but must express a variety of proteins.  This is accomplished via alternative 
mRNA  splicing,  which  results  in  the  production  of  various  mRNAs  from  a  single  RNA 
precursor.  Three types of mRNA are transcribed:  a full-length unspliced mRNA that will be 
packaged  as  the  viral  genome;  singly-spliced  mRNA  encoding  the  major  protein  precursors; 
small multi-spliced transcripts.  Most cellular mRNAs are fully spliced before nuclear export, but 
lentiviruses  by  necessity  must  export  unspliced  or  singly-spliced  transcripts.    This  is 
accomplished through action of the Rev protein.  Rev binds to the Rev-response element (RRE) 
located near the end of the env gene and mediates mRNA transport to the cytoplasm.  Aside from 
these two accessory proteins, lentiviruses may express other regulatory proteins. [For review (36, 
98, 99, 129, 186)] 
Another key lentivirus feature is their ability to infect nondividing cells.  It is this ability 
that  allows  lentiviruses  such  as  HIV-1  and  EIAV  to  infect  their  target  cells,  which  include  
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quiescent T cells for HIV-1 and macrophages for both viruses (127, 128, 221).  The PIC reaches 
the nucleus through the nuclear pore complex.  Because of the size of the PIC, entry into the 
nucleus must require active transport rather than passive diffusion through the NPC (28, 49, 88, 
130, 212).  The translocation of the HIV-1 PIC into the nucleus has been a field of extensive 
study, and researchers have sought to identify viral components critical for this process as well as 
the cellular machinery involved.  This process will be discussed in further detail below. 
Equine infectious anemia virus (EIAV) 
HIV-1 is the best-known lentivirus, but a number of other lentiviruses also induce long-term 
persistent infections that cause diseases which can have serious health ramifications for the host.  
One such virus is EIAV.  EIAV is a member of the non-primate lentivirus group, which also 
includes visna/maedi virus (VMV), caprine arthritis-encephalitis virus (CAEV) and feline and 
bovine immunodeficiency viruses (FIV and BIV).  EIAV was the first retrovirus associated with 
disease, being identified as a causative “filterable agent” in 1904.  EIAV is transmitted through 
blood exposure, either through unsterile needles/transfusions from infected carriers, or through 
insect vectors (69, 70).  The most common method of transmission is through bites from horse 
flies or other hematophagous insects.  The virus is carried on the insect’s mouth parts after a 
blood meal from an infected carrier (44, 94, 101).  The pathogenesis of EIAV infection is unique.  
The course of the disease can be divided into three distinct phases.  The acute phase occurs 
shortly after infection and is marked by fever and anemia.  These symptoms are usually mild and 
few animals succumb to the disease at this point (126, 153).  The next phase is called the chronic 
phase.  This stage lasts 1-12 months and is characterized by recurrent cycles of severe anemia 
and high titers of circulating virions (102, 126, 153, 164).  If the infected animal survives the  
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chronic phase, it enters the asymptomatic phase.  In contrast to other lentiviruses such as HIV-1, 
in  which  carriers  slowly  succumb  to  degenerative  diseases  within  a  few  years  of  infection, 
EIAV-infected horses transition from the chronic phase to a stage marked by a lack of clinical 
symptoms.  However, carriers remain infected for life and can still transmit the virus through 
blood exposure.  During the asymptomatic phase, viremia is extremely low (37, 101, 116, 126, 
180, 190).  This phase is reversible, and animals may re-enter the chronic phase and recurrent 
bouts  of  anemia.    Immune  response  is  clearly  critical  for  maintenance  of  the  asymptomatic 
phase, as administration of immunosuppressive drugs leads to disease recrudescence (41, 119, 
174, 209). 
EIAV undergoes the life cycle steps typical of all retroviruses and exhibits characteristic 
lentiviral structure.  However, it does have some unique features that differentiate it from other 
lentiviruses, which will be summarized below.  
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Figure 1-1.  The infection cycle of EIAV and other retroviruses.  
From Leroux et al.  EIAV:  what has HIV’s country cousin got to tell us? Vet. Res. 35 (2004) 485-512  
EIAV entry and the cellular receptor.  EIAV is an exclusively macrophage-tropic virus.  This 
particular type of tropism is shared by VMV and CAEV, which infect sheep and goats and are 
referred to as small ruminant lentiviruses (SRLVs).  SRLVs infect monocytes and macrophages.  
Infection of monocytes requires their subsequent maturation to macrophages for active virus 
replication  (158,  159,  168,  195).    EIAV  infects  circulating  blood  macrophages  which  then 
disseminate the virus to mononuclear phagocytes in various organs.  The main sites of virus 
replication are macrophages in the liver and spleen (168).   
The viral envelope SU region (gp90) is predicted to be similar to that of HIV-1 (73, 74).  
This region is the predominant site of antigenic variation (127, 128, 225).  A cellular receptor for  
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EIAV has been identified fairly recently.  Equine lentivirus receptor-1 (ELR1) is a member of 
the tumor necrosis factor receptor (TNFR) superfamily.  Other retroviruses, including FIV and 
avian sarcoma-leukosis virus (ASLV), also use TNFR proteins as receptors (3, 25).  ELR1 is 
sufficient for EIAV entry; no coreceptors are needed, in contrast to HIV-1 and other lentiviruses.  
In  addition,  ELR1-mediated  entry  of  EIAV  is  pH-dependent  (106,  221).    A  complex  of  a 
proteoglycan  and  a  protein  kinase  has  been  identified  as  a  functional  receptor  for  VMV, 
suggesting  that  ungulate  lentiviruses  with  exclusive  macrophage  tropism  such  as  EIAV  and 
VMV may have a common entry mechanism in which a single receptor protein mediates pH-
dependent endocytosis (12, 27, 106).  In addition, it is hypothesized that those lentiviruses with 
monocyte/macrophage tropism, like the ungulate lentiviruses, have evolved to use receptors that 
will  activate  normally  quiescent  target  cells,  leading  to  enhanced  gene  expression  and  virus 
replication  in  these  nondividing  cells.    TNFR  proteins  activate  diverse  signal  transduction 
pathways  and  the  VMV  receptor  complex  is  associated  with  activation  of  mitogen-activated 
protein kinase pathways (12, 13, 139, 192).  Current research is ongoing to determine the cellular 
expression profile of the ELR1 receptor in vivo.  NIH 3T3 cells expressing ELR1 and equine 
cyclin T1 are permissive for EIAV replication.  In addition, ELR1 is expressed in all cell types 
permissive  for  EIAV  infection,  including  macrophages,  equine  dermal  fibroblasts  and  fetal 
equine kidney cells.  ELR1 has not been detected in nonpermissive cell types, such as equine 
lymphocytes, simian or human cell lines (222).  In addition, it is not yet known whether ELR1 is 
the only functional cellular receptor for EIAV. 
EIAV proteins.  The EIAV genome is 8.2 kb, the smallest and simplest of the lentiviruses (Fig. 
1-2B).    Gag  and  pol  genes  are  translated  from  the  full-length  viral  RNA  (162).    The  Gag 
polyprotein (Pr55) is cleaved by protease into four structural proteins:  MA (p15), CA (p26), NC  
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(p11) and p9.  EIAV MA is associated with the inner face of the viral membrane and shows 
many structural similarities with HIV-1 MA.  However, HIV-1 MA is myristylated and EIAV 
MA is not (89).  The p9 protein is analogous to late domain proteins such as HIV-1 p6.  The p9 
protein is involved in particle budding but also plays a role in the nuclear import of proviral 
DNA (33, 105, 150, 175, 176, 198).  Pol products include RT, PR, IN, and a dUTPase (138, 194, 
204).  The dUTPase protein p15 is essential for EIAV replication in macrophages.  Env encodes 
gp90 and gp145 (128).  Besides gag, pol, and env, EIAV has three additional reading frames that 
encode the proteins Tat, Rev and S2 from multispliced transcripts (177, 196).  Rev mediates the 
transport of viral mRNAs from the nucleus to the cytoplasm by interacting with an RRE (15, 35, 
126, 147).  EIAV Tat interacts with the viral LTR through a TAR element to drive transcription.  
Tat recruits the pTEFb complex, which is composed of CDK9 kinase and cyclin T1.  Despite the 
fact  that  EIAV  Tat  and  TAR  elements  are  highly  divergent  from  those  of  HIV-1,  a  similar 
process involving cyclin T1 is involved in HIV-1 gene expression (4, 18, 22, 126, 137, 200).  
Murine  NIH  3T3  cells  engineered  to  express  the  receptor  ELR1  and  equine  cyclin  T1  are 
permissive for EIAV replication, indicating that these two factors are sufficient for infection and 
murine cells do not contain negative host factors that block infection (222).  EIAV is unique 
among lentiviruses in having only one accessory gene besides tat and rev.  This is the S2 gene. 
The S2 protein is not required in vitro for virion production and is not packaged into virions.  
However, it is present in all EIAV strains and is required for infection in vivo.  Currently, it is not 
known what the exact function of S2 is, although a yeast two-hybrid screen has identified several 
cellular proteins that interact with S2.  One possible function to date is to increase the gene 
expression of pro-inflammatory cytokines and chemokines (39, 40, 62, 132, 133, 170, 188).  
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Figure 1-2.  The EIAV virion (A) and proviral genome (B).
From Leroux et al.  EIAV:  what has HIV’s country cousin got to tell us? Vet. Res. 35 (2004) 485-512  
 
EIAV capsid (CA).  The EIAV core complex within the lipid membrane of the virion is mostly 
composed of CA protein (p26).  When virions are viewed by thin-section electron microscopy, 
the characteristic cone shape of the inner viral core is easily observed (Fig. 1-3A).  This type of 
structure  is  called  a  fullerene  cone:    a  variably  curved  shell  composed  of  hexamers  and 
pentamers of CA (Fig. 1-3B) (81).  The EIAV viral core complex exhibits the typical cone-
shaped morphology that is the hallmark of lentiviruses.  Like HIV-1 CA, EIAV CA forms dimers 
in solution.  However, in mature lentiviral virions, CA condenses to form a fullerene cone:  a 
hexagonal  lattice  of  CA  monomers  which  are  closed  by  pentons  [reviewed  (80)].    Each 
hexagonal unit of the fullerene cone represents a hexameric ring of six CA monomers (Fig. 1-
3C) (24, 78, 124, 134, 160).  These fullerene cone structures can be purified from detergent-
treated EIAV virions and retain their cone shape under electron microscopy [(182), Appendix].   
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The simple purification of these complexes and their ability to retain their three-dimensional 
state after isolation suggests that EIAV cores may be unusually stable.   
Fullerene Cone
Capsid Hexamer
A B C
 
Figure  1-3.    The  lentiviral  core  complex  is  a  fullerene  cone  composed  of  CA  hexamers.    (A)  An  electron 
micrograph of a HIV-1 virion.  (B) The structure of a fullerene cone.  A single CA hexamer is highlighted in yellow.  
(C) The structure of an individual CA hexamer, with each of the six CA monomers portrayed in a different color. 
 
The structure of EIAV CA has been solved (107).  EIAV CA has 30% sequence identity with 
HIV-1 CA (87).  Like HIV-1 CA, EIAV CA consists of seven α-helices forming the N-terminal 
domain (NTD) and four α-helices forming the carboxyl-terminal domain (CTD), with a linker 
region between the two (Fig. 1-4).  Like HIV-1, EIAV CA has a proline-rich loop between 
helices 4-5 in the NTD.  This loop in HIV-1 CA has 4 prolines in 17 amino acid residues, and 
assumes both cis and trans conformations (76, 77, 82, 210).  The EIAV proline-rich loop has 7 
prolines in 19 residues and adopts only the trans conformation in the crystal (107).    
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Amino Terminal Domain
Carboxy Terminal Domain
 
Figure 1-4.  The EIAV and HIV-1 CA share similar domain structures.  The proline-rich loop found in the amino-
terminal domain of both CA proteins is indicated with black arrows.  Figure adapted from (30). 
 
The HIV-1 CA is the target of several cellular host factors that can affect infectivity, primarily 
during the uncoating step but also during nuclear import.  EIAV CA has also been shown to 
interact with some of these same factors (see below).  These similarities between the CA proteins  
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of these two viruses, along with the ease of isolating intact EIAV core structures, make EIAV an 
attractive candidate for the study of lentiviral capsids. 
Cellular host factors:  uncoating.  The incoming  retroviral CA is a target for cellular host 
factors  that  modulate  the  uncoating  process.    Host  factors  may  influence  uncoating  either 
positively or negatively.  One class of factors that negatively affect uncoating have been called 
restriction factors (93, 97, 120, 165, 166).  The TRIM5α proteins are an example of restriction 
factors.  It has been shown that TRIM5α from Old World monkeys such as the rhesus macaque 
binds the HIV-1 capsid and accelerates the disassembly of the core complex.  This leads to a 
severe block in HIV-1 infection that usually occurs prior to reverse transcription.  In addition, 
human TRIM5α exhibited similar inhibitory effects on N-MLV infection (52, 53, 173, 199).  
EIAV infection is severely restricted by rhesus TRIM5α and restricted to a lesser extent by 
human TRIM5α (92, 207). 
Cyclophilin  A  is  an  example  of  a  host  factor  that  positively  modulates  uncoating.  
Cyclophilin A (CypA) interacts with the HIV-1 CA.  It is a peptidyl prolyl isomerase whose 
normal cellular function is catalysis of the cis/trans isomerization of proline peptide bonds (84).  
CypA binds HIV-1 CA via the proline-rich loop located in the NTD of CA.  Residues Gly89 and 
Pro90  are  the  primary  CypA  recognition  motif  (76,  210,  224).    Disruption  of  this  binding, 
whether through amino acid alteration or application of the drug cyclosporine A (CsA), results in 
decreased  HIV-1  infection  in  certain  cell  types  (76,  109,  114,  136,  217).    EIAV  CA  has  a 
proline-rich loop very similar to that of HIV-1; however, treatment of cells with CsA does not 
affect  infectivity,  suggesting  that  CypA  binding  is  not  required  for  EIAV  infectivity.    The  
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proline-rich loop region of EIAV is an attractive candidate for further study, due to this region 
being critical for infectivity of several other lentiviruses. 
Cellular host factors:  nuclear import.  The early stages of the retroviral infection cycle are 
often pictured sequentially, with reverse transcription and integration happening after uncoating 
has already taken place.  Both reverse transcription and integration involve large nucleoprotein 
complexes.  Reverse transcriptase converts viral RNA into double-stranded DNA in the reverse 
transcription complex (RTC) (65, 66).  Viral DNA enters the nucleus in the form of the PIC, at 
which time it is integrated into the host genome (19, 26, 72).  Initially, it was believed that 
uncoating must be complete before reverse transcription could begin, as very little CA remains 
associated with the RTC (65, 66, 100).  However, HIV-1 is able to initiate reverse transcription 
within the intact core complex in vitro (223).  
Unlike simple retroviruses, lentiviruses are able to infect non-dividing cells, such as the 
macrophage, the host cell type of EIAV.  Therefore, these viruses must be able to cross the 
nuclear envelope that separates nucleus and cytoplasm (201).  Lentiviruses are believed to enter 
the nucleus through the nuclear pore complex (NPC) (112, 131).  Molecules can move through 
the NPC either by passive diffusion or active transport.  As the PIC is too large to enter by 
diffusion (> 9 nm limit), it must be actively transported by the cellular import machinery (28, 49, 
88,  130,  152,  212).    Various  studies  have  identified  several  components  of  NPC  transport 
machinery involved in HIV-1 PIC nuclear entry, including nucleoporins (NUPs), importins and 
karyopherins (8, 58, 75, 220).  More recently, siRNA screens have identified critical transport 
proteins by examining the effects of depletion of said proteins on HIV-1 infection (21, 118, 226).  
One such protein identified was transportin 3 (TNPO3).  TNPO3 is a member of the karyopherin  
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β superfamily and transports proteins with serine/arginine motifs into the nucleus (110, 122, 
123).  Additional proteins identified were NPC components NUP153, NUP358 and NUP155 (21, 
118).  On the viral side of nuclear transport, several HIV-1 proteins have been assigned roles as 
well.    These  include  MA,  Vpr  and  IN  as  well  as  the  DNA  flap  formed  during  reverse 
transcription (104).  However, a definitive role for these proteins has not been established, and 
viruses with these proteins mutated in combination could still infect nondividing cells (50, 64).  
Yamashita et al. have shown that the definitive requirement for nuclear import of the PIC is 
instead CA (215, 216).  This suggests that CA is required beyond the step of core disassembly 
and that the minimal amounts of CA that remain associated with the nucleoprotein complexes 
post-uncoating play a critical role in subsequent early infectivity steps. 
Because TNPO3 was identified as an IN binding factor in a yeast two-hybrid screen, it 
was initially thought that the requirement of HIV-1 for TNPO3 in nuclear import would map to 
IN (34).  However, it mapped instead to CA.  CA mutant N74D does not require TNPO3 for 
infection  (7,  48,  121,  125,  140,  187,  205).    In  addition,  the  requirement  for  NUP153  is 
determined by CA as well.  Matreyek et al. demonstrated that chimeric HIV-1 viruses containing 
CA from MLV were insensitive to NUP153 depletion (151). 
To  date,  most  studies  of  nuclear  import/CA  requirements  have  focused  on  HIV-1.  
However, the interaction of HIV-1 with CypA has complicated interpretation of some data.  CsA 
treatment renders wild-type HIV-1 insensitive to NUP153 knockdown (151).  However, SIVmac 
is highly sensitive to NUP153 knockdown despite not binding CypA (20, 151).  In addition, the 
HIV-1 CA mutant N74D is insensitive to TNPO3 knockdown but is  more sensitive to CsA 
treatment and is also unable to infect macrophages (7).  Aside from CypA’s effects on nuclear  
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import,  Li  et  al.  have  demonstrated  that  the  CypA/CA  interaction  can  either  stabilize  or 
destabilize the incoming HIV-1 CA, depending on the target cell type (136).  EIAV has a loop 
region similar to HIV-1’s CypA-binding loop but does not bind CypA.  Therefore, experiments 
involving EIAV CA and nuclear import should be easier to interpret without confounding results 
due to CypA.  A study investigating the TNPO3 domain required for virus import has shown that 
EIAV is extremely sensitive to TNPO3 depletion and that the same TNPO3 motifs (the cargo-
binding domain) are required for HIV-1 and EIAV infection (140). 
Recent  studies  have  shown  that  the  role  of  CA  does  not  end  at  the  uncoating  step.  
Rather, CA remains a critical infectivity factor throughout the early stages of infection up to 
integration of the provirus.  Due to its similarities to HIV-1 CA and its purported stability, we 
postulated that the EIAV CA would be an attractive target for mutagenesis.  As both HIV-1 and 
EIAV  contain  the  amino-terminal  proline-rich  loop,  and  changes  to  this  loop  affect  HIV-1 
uncoating, we expected that the introduction of changes in this region would affect infectivity 
during the uncoating step.  We aligned the loop regions of HIV-1 and EIAV and introduced 
amino acid substitutions at conserved residues, excluding the prolines (Fig. 1-5).  Chapter 2 
contains the results of experiments on these mutants.  Briefly, we saw that some changes did 
affect infectivity, in both negative and positive directions.  For those mutants that had deleterious 
effects, infectivity was abrogated to a severe degree.  Unexpectedly, the changes did not affect 
uncoating or reverse transcription.  However, those mutants with infectivity defects exhibited 
markedly decreased production of 2-LTR circles and proviral DNA.  This suggests that these 
particular  mutants  have  defects  in  nuclear  import,  demonstrating  that  EIAV  CA  should  be 
investigated further as a target for the nuclear import process.  These mutants in particular may  
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be useful tools for future research investigating the involvement of CA in the nuclear import of 
lentiviruses.  
 
Figure 1-5.  Amino acid substitutions introduced into the EIAV CA proline-rich loop.  The loop is highlighted in 
pale gray.  Amino acids chosen for substitution are indicated in red. 
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Retroviral Gag proteins have critical roles in the infection of target cells during early post-entry 
events.  In particular, the retroviral capsid protein (CA) has been implicated in many early 
infectivity steps.  Viruses must disassemble properly after target cell entry.  Several studies have 
shown that CA is critical to this step, which is termed “uncoating” (13, 18). Mature lentiviruses 
contain a distinct cone-shaped core comprised of CA monomers.  CA monomers interact at 
several molecular interfaces to form the conical core, including C-terminal domains involved in 
dimerization and N-terminal domains involved in hexamerization (15, 35, 46).  This core 
complex begins uncoating soon after the fusion of viral and cell membranes (13, 19).  Very little 
CA protein can be found associated with the reverse transcription complex (11, 12, 23).  Changes 
in CA that affect the stability of this core complex can severely abrogate infectivity (13).  In 
addition, the incoming viral CA is the target of several host factors that can affect infectivity.  
The host cytosolic protein cyclophilin A (CypA) binds to the proline-rich loop in the N-terminal 
domain of HIV-1 CA (14, 15, 17, 42, 61).  Changes in this region that affect CypA binding to 
CA can be severely detrimental to core disassembly and infectivity (4, 39, 59, 63, 70).  Certain 
host restriction factors target CA and interrupt retroviral infection at the uncoating step.  The 
proteins TRIM5α and TRIMCyp bind the incoming capsid of certain retroviruses and accelerate 
core disassembly (6, 8, 47, 55, 60).  Changes in CA residues critical for these interactions can 
allow the incoming viral capsid to escape TRIM5α-mediated disassembly or cause previously 
nonrestricted retroviruses to become TRIM5α targets (36, 37, 40). 
  More recent studies have shown that CA’s role in the infection process does not end at 
uncoating.  Reverse transcription and subsequent viral cDNA integration take place within 
nucleoprotein complexes that may retain components of the viral core complex (3, 11, 12, 23,  
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45).  Although certain retroviruses require the dissolution of the nuclear membrane during 
mitosis, lentiviruses such as HIV-1 or equine infectious anemia virus (EIAV) can infect 
nondividing cells and therefore are believed to cross the nuclear membrane by passing through 
the nuclear pore complex (27, 33, 54).  The ability of HIV-1 to infect growth-arrested cells has 
been mapped to CA (67-69).  Several recent studies have investigated the requirements for 
various nuclear import factors during infection, such as nucleoporin Nup153 or transportin 3 
(TNPO3).  The requirements for these factors map to HIV-1 CA and not to the integrase protein 
as previously thought (1, 5, 29, 30, 41, 44, 56, 62, 72). 
  In this study we investigated the effects of changes in the EIAV CA on virus infection.  
EIAV is an attractive candidate for capsid protein studies as it is a lentivirus like HIV-1 and also 
contains an N-terminal proline-rich loop that is very similar to HIV-1’s Cyp A-binding loop (26).  
Changes in this loop exert various effects on HIV-1 infection, in some cases dependent on the 
level of CypA expression in the host cell.  EIAV infection is not apparently influenced by CypA.  
Nonetheless, because of the presumed exposure of this loop on the EIAV capsid, we expected 
that this region of the EIAV CA would be critical for infection and that changes in this region 
would yield interesting phenotypes.  Our findings show that alteration of the loop region did in 
fact affect EIAV infectivity.  We identified three mutants that demonstrate EIAV CA is also 
critical for nuclear import.  The requirement of CA for proper nuclear import and subsequent 
proviral integration in both EIAV and HIV-1 highlights the universality of lentivirus CA as a 
nuclear transport/entry determinant. 
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Materials & Methods 
 
Production of recombinant EIAV expressing green fluorescent protein (GFP). 
The pEV53 plasmid encoding the EIAV Gag/Pol polyprotein and the pSIN6.1CeGFPW plasmid 
encoding enhanced green fluorescent protein (eGFP) have been described previously (48-51).  
Point mutations were introduced into the region of pEV53 encoding CA using the QuikChange 
Lightning Site-Directed Mutagenesis Kit (Stratagene).  Vesicular stomatitis virus protein G 
(VSV-G)-pseudotyped EIAV-GFP virions were made by cotransfecting 293T cells with wild-
type (wt) or CA mutant pEV53 vector, pSIN6.1CeGFPW vector, and a pHCMV plasmid 
expressing VSV-G.  Lipofectamine 2000 transfection reagent was used (Invitrogen).  Virus-
containing supernatant was harvested 48 h post-transfection.  All virus-containing supernatants 
were cleared of debris by low-speed centrifugation and then concentrated by centrifugation in a 
Beckman SW 28 rotor at 27000 rpm for 2 h.  Each virus stock was quantitated by a standard 
reverse transcriptase (RT) activity assay (25).  Stocks were stored in aliquots at –80°C. 
Cell culture and infectivity assays. 
Human 293T cells (ATCC CRL-11286) and the equine dermal cell line ED (ATCC CCL-57) 
were acquired from the American Type Culture Collection.  Cf2-LPCX cells and Cf2-TRIM5αRh 
cells have been described previously (60).  293T and ED cells were grown at 37°C in Dulbecco 
modified Eagle medium (Invitrogen).  All media were supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin.  In addition, media for Cf2-LPCX and Cf2-TRIM5αRh 
cells were supplanted with 5 ng/ml puromycin.  For infection, Cf2-LPCX, Cf2-TRIM5αRh and 
ED cells were seeded at a density of 5 x 10
5 cells/well in 6-well plates.  Equal amounts of EIAV 
viruses, normalized by RT activity, were used to infect cells for 4 h at 37°C.  Unabsorbed virus 
was washed out with phosphate-buffered saline (PBS) and the cells were cultured with fresh  
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media.  Cells were harvested 48 h after infection and fixed in PBS containing 4% formaldehyde.  
The percentage of infected, GFP-positive cells was determined by fluorescence-activated cell 
sorting (FACS) using FACScan (Becton Dickinson). 
Viral protein analysis and Western blotting. 
293T cells were transfected with the pEV3 plasmid encoding either wt. or mutant EIAV Gag/Pol 
polyprotein.  Cells were harvested and lysed 48 h post-transfection.  The expression levels of the 
cell-associated Gag proteins were analyzed by Western blotting with a polyclonal anti-EIAV 
serum (LADY), gift from the Montelaro lab (Univ. of Pittsburgh), and an anti-horse IgG 
horseradish peroxidase (HRP)-conjugated antibody (Abcam), respectively.  Virions released into 
the transfected cell supernatants were filtered (0.45- m pore size).  Virus-containing supernatant 
was normalized by volume and the virions lysed.  Viral lysates were Western blotted using the 
same antibody combination described above. 
Electron microscopy of virus particles. 
Ten ml of transfected cell supernantant containing wt or mutant virus was centrifuged at 4°C for 
2 h at 27,000 rpm in a Beckman SW41 rotor.  Pelleted viral particles were fixed with 
glutaraldehyde and analyzed by thin-section electron microscopy at the Harvard Medical School 
Electron Microscope Facility. 
Quantitative real-time PCR analysis of EIAV-specific viral DNA species. 
Virus stocks derived from transfection of 293T cells were treated with 20 U of DNase I 
(NEB)/ml for 60 min at room temperature.  Approximately 1 x 10
5 Cf2-LPCX cells were 
infected with 8000 cpm (RT activity) of wt EIAV-GFP virus or mutant EIAV-GFP virus.  As a 
control, cells treated with 150 µM azidothymidine (AZT) were infected with wt EIAV-GFP 
virus. As another control, cells were incubated with wt EIAV-GFP virus lacking envelope  
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glycoproteins (Env-).  Genomic DNA was isolated at various time points after infection using the 
DNEasy Blood and Tissue Kit (Qiagen), and 250 ng of genomic DNA was used for quantitative 
PCR amplification.  The conditions for quantitative real-time PCR of early and late DNA 
products have been described previously (25).  The primer/probe set used to amplify early DNA 
products (minus-strand strong-stop DNA) has been described previously (25).  The primer/probe 
set used to detect late DNA products (eGFP DNA) was as follows:  eGFP-FW (5’- 
CGACGGCAACTACAAGAC -‘3), eGFP-RV (5’-GTCCTCCTTGAAGTCGATGC-3’), and 
eGFP probe (5’-(6-carboxyfluorescein)-CACCCTGGTGAACCGCATCG-(5-
carboxytetramethylrhodamine)-3’).  For persistent viral DNA (vDNA), the isolated genomic 
DNA was subjected to quantitative real-time PCR using the eGFP primer/probe set.  Standard 
curves for each DNA species were created as described previously (25). 
  For nuclear unintegrated DNA (2-LTR circles), genomic DNA was extracted as described 
above and 250 ng of genomic DNA was used for quantitative PCR amplification.  The primers 
used were 2LTR-FW (5’-TGTGCAGACTTGCGAACCATG-3’) and 2LTR-RV (5’-
CGAATTCCAGCGTCTGAGTTAC-3’).  A standard curve was created to calculate the number 
of copies of 2-LTR circle DNA.  The 2LTR primer set was used to amplify a fragment of 
approximately 860 nt from genomic DNA extracted from cells infected with wt EIAV-GFP 
(Platinum Blue PCR Supermix, Invitrogen).  The resulting fragment was cloned into the pCR 2.1 
vector contained in The Original TA Cloning Kit (Invitrogen).  The resulting plasmid was used 
to establish a standard curve, as previously described (25).  Quantitative real-time PCR was 
carried out using the QuantiTect SYBR Green PCR Kit (Qiagen).  After initial incubations at 
50°C for 2 min and 95°C for 10 min, 40 rounds of amplification were carried out at 95°C for 15 
sec, 60°C for 30 sec and 72°C for 1 min 15 sec.  Reactions were carried out in the ABI Prism  
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7700 sequence detection system and analyzed with ABI Prism SDS software (Applied 
Biosystems). 
Fate-of-Capsid assay. 
The assay to examine the fate of EIAV capsids in the cytosol of newly-infected Cf2-LPCX cells 
was performed essentially as described previously (60).  Concentrated virus in approximately 
100-500  l was incubated with 5 x 10
6 Cf2-LPCX cells in a total of 5 ml of media in a T-75 
flask.  The cells and virus were initially incubated for 30 min at 4°C and then shifted to 37°C.  At 
4 h post-infection, the cells were washed with PBS and then incubated with 10 ml of fresh 
medium for the remainder of the infection.  The cells were then washed in ice-cold PBS and 
lysed in 2.5 ml of hypotonic lysis buffer (10 mM Tris-HCl [pH 8.0], 10 mM KCl, 1 mM EDTA) 
by Dounce homogenization.  After the cell debris was removed by centrifugation for 5 min at 
2,000 x g, 2 ml of the clarified lysate was layered onto a 7-ml 50%-sucrose cushion and 
centrifuged at 125,000 x g for 2 h at 4°C.  After centrifugation, 100  l of the topmost part of the 
supernatant was collected.  The pellet was resuspended in 120  l of 1X sodium dodecyl sulfate 
sample buffer.  The supernatant and pellet fractions were subjected to Western blotting analysis 
of CA proteins with an anti-EIAV polyclonal serum. 
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Results 
Effects of changes in the proline-rich CA loop on Gag expression, processing, and 
morphology 
The proline-rich loop (residues 80-119) of the EIAV CA protein protrudes from the helical 
bundle of the N-terminal domain of CA.  Thus, this loop is expected to be exposed on the 
exterior surface of the assembled CA and corresponds to the CypA-binding loop of HIV-1.  To 
assess the effects of changes in this proline-rich loop region on viral infectivity, we introduced 
point mutations in the CA-encoding region of a recombinant, single-round EIAV vector (Fig. 2-
1A).  We examined whether the expression and processing of the Gag polyprotein were affected 
by these changes.  293T cells were transfected with plasmids encoding either wt or mutant EIAV 
Gag/Pol proteins.  Forty-eight hours after transfection, both cell-associated and virion-associated 
Gag proteins were analyzed by Western blotting using a polyclonal anti-EIAV serum (Fig. 2-1B 
and C).  Several mutants appeared to be defective, exhibiting either greatly reduced (H85D, 
L87M, L92R, V93A, E115A) or undetectable steady-state levels of expression (G98E, Q117A, 
E119A) of Gag polyproteins.  In addition, the G42S mutant appeared to exhibit a defect in Gag 
precursor processing.  These results suggest that several of the changes introduced into the CA 
region affect Gag expression, but not virion assembly and release.  
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Figure 2-1.  Effects of EIAV CA changes on Gag processing. 
The aligned amino acid sequences of the proline-rich loops of HIV-1 (blue) and EIAV (black) are shown (A).  
Numbering corresponds to the amino acid number in the HIV-1 CA protein.  Red arrows indicate mutated amino 
acids in EIAV CA, with the corresponding change below the arrow.  (B)  Cell lysates from 293T cells transfected 
with plasmids encoding wt and mutant EIAV Gag polyproteins, with positions of weight markers indicated.  Total 
cellular proteins were subjected to Western blotting using an anti-EIAV polyclonal serum.  (C)  Virion-containing 
cell supernatants were centrifuged.  Solubilized virion pellets were analyzed by Western blotting using an anti-EIAV 
polyclonal serum. 
 
 
Effects of CA changes on EIAV infectivity 
 
To assay the effects of the CA changes on infectivity, Cf2-LPCX cells were challenged with 
various amounts of wt and mutant EIAV-GFP (Fig. 2-2).  Several mutants exhibited levels of 
infectivity substantially lower than that of wt EIAV (G42S, R84D, H85D, G98E, M102A, 
Q117A and E119A).  Of these mutants, G42S, H85D, G98E, and Q117A show greatly reduced 
expression or processing of Gag polyproteins, which likely reflects conformational problems that  
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contribute to their infectivity defects.  The three remaining mutants, R84D, M102A and E119A 
exhibit normal Gag precursor processing and virion production/release.  In addition, three 
mutants (L87M, N89A and N89E) appear to be slightly more infectious than wt EIAV.   
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Figure 2-2.  Infectivity of EIAV CA mutants in Cf2-LPCX cells. 
Cf2 cells containing the empty retroviral vector LPCX were challenged with the indicated amounts of wt or mutant 
EIAV-GFP viruses.  After 48 h, the percentage of GFP-positive cells was determined by FACS.  Mutants are color-
coded based on their percentage of infectivity as compared to wt EIAV (black line).  Red:  0-15% infectivity; 
yellow:  30-75% infectivity; green:  higher infectivity than wt EIAV.  cpm, counts per minute as determined by 
reverse transcriptase activity.   
 
As horses are the natural hosts of EIAV, we wished to determine the effects of these CA changes 
on infectivity in an equine cell line.  Equine dermal (ED) fibroblasts were challenged with 
various amounts of wt and mutant EIAV-GFP.  The infectivity profiles of the mutants in the ED 
cells were very similar to those in Cf2-LPCX cells.  Namely, poor expressors/producers were not 
infectious, while R84D, M102A and E119A exhibited decreased infectivity.  L87M and N89A  
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were slightly more infectious than wild-type EIAV (Fig. 2-3A).  However, the N89E mutant, 
which replicated slightly more efficiently than wt EIAV in Cf2-LPCX cells, did not exhibit this 
phenotype in ED fibroblasts. 
The TRIM5α protein from rhesus macaques has been shown to restrict EIAV infectivity 
(71).  Cf2 cells expressing the rhesus TRIM5α protein were challenged with various amounts of 
wt and mutant EIAV-GFP virus.  Most mutants were strongly restricted by rhesus TRIM5α, 
similar to wt EIAV.  However, the three mutants that exhibited increased infectivity compared to 
wt EIAV in Cf2-LPCX cells also exhibited less restriction by rhesus TRIM5α in the matched 
Cf2 cells (Fig. 2-3B). 
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Figure 2-3.  Infectivity of EIAV CA mutants in ED cells and Cf2 cells expressing rhesus TRIM5α α α α. 
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Figure 2-3 (Continued).  Infectivity of EIAV CA mutants in ED cells and Cf2 cells expressing rhesus 
TRIM5α α α α. 
Different amounts of wt or mutant EIAV-GFP were used to infect either ED cells (A) or Cf2-TRIM5αRh cells (B).  
The results of a single experiment typical of those obtained in three independent experiments are shown.  The color 
of each CA mutant represents its infectivity in Cf2-LPCX cells (Fig. 2-2).   cpm, counts per minute as determined by 
reverse transcriptase activity. 
 
 
Effects of CA changes on EIAV capsid morphology 
 
Some changes in the HIV-1 CA protein have been shown to alter the characteristic conical shape 
of the mature capsid.  These changes have often led to decreases in infectivity (21, 64).  To 
examine whether the changes introduced into EIAV CA affect core formation, we analyzed the 
morphology of wt and mutant virions by thin-section electron microscopy (EM).  All mutants 
were examined, with the exception of the poor producers G42S, H85D, G98E, and Q117A.  
Mature, conical cores were observed for the wt and CA mutant viruses (Fig. 2-4A).  The ratio of 
the amount of classical conical cores to cores with nonconical morphology was similar for wt  
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and mutant virions (Fig. 2-4B).  Apparently, the formation and morphology of the mature virion-
associated core is not significantly affected by the introduced changes in the CA protein.  
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Figure 2-4.  Thin-section electron microscopy of EIAV virions. 
Virions were purified from the supernatant of 293T cells transfected with plasmids encoding wt or mutant EIAV 
Gag/Pol proteins and fixed with gluteraldehyde for thin-section electron microscopy.  (A)  Examples of virions with 
evident conical cores are shown.  (B)  One hundred five particles were counted and scored as conical or nonconical 
for each CA mutant.  Light blue bars indicate virion particles scored as conical; dark blue bars represent virions 
scored as nonconical. 
 
Effects of CA changes on EIAV uncoating in Cf2-LPCX cells 
 
To gain insight into the infectivity defects caused by the CA changes, we studied the uncoating 
of the wt and CA mutant viruses using a previously developed fate-of-capsid assay (60).  This 
assay allows us to measure the amounts of particulate and soluble forms of retroviral CA present 
in the cytosol of infected cells.  The capsids in the particulate, cytosolic fraction are associated  
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with viral RNA and also exhibit densities that are comparable to those of intact capsids prepared 
by detergent treatment of virions (13, 28, 53, 60, 65).  The appearance of particulate CA in the 
cytosol depends upon viral entry and is also affected by the restriction factors TRIM5α or 
TRIMCyp (6, 7, 24, 53, 60).  VSV-G-pseudotyped virions continue to enter cells up to 16 hours 
post-infection; therefore the steady state levels of cytosolic CA in the particulate fraction reflect 
both entry and decay of the capsids.  Virus entry is apparently not influenced by the particular 
CA variant; thus, comparing the steady-state levels of cytosolic CA in the particulate fraction 
allows an assessment of the conversion of particulate CA to soluble CA, which is measured in 
the supernatant (SN) fraction.  The fate-of-capsid assay also allows a study of the decay of these 
two forms of CA (6, 60).  Because previous studies employing this assay have not used EIAV, 
we wished to first ascertain the optimal time at which to view the conversion of particulate CA to 
cytosolic CA.  Namely, this point would occur when the signal intensity in the particulate 
fraction peaks, before it begins to decay.  To determine at what time post-infection this point 
occurs, Cf2-LPCX cells were infected with either VSV-G-pseudotyped EIAV virus, or with 
EIAV virion-like particles that did not have an envelope glycoprotein (Env-).  Infection was 
allowed to proceed for a given amount of time, after which the cells were harvested and lysed as 
previously described (60). Figure 2-5 shows the results of this experiment, which creates a time 
course in which the entry of CA and the conversion of particulate CA (Pellet) to soluble CA 
(SN) can be followed (Fig. 2-5A).  In addition, the band intensity is plotted versus time to show 
the rise and decay of signal in the particulate fraction and the appearance of CA in the soluble 
fraction (Fig. 2-5B).  Half-lives were calculated for the decay of signal in the pellet fraction (11.3 
h post-infection) and the increase in signal in the supernatant fraction (9.7 h post-infection).  
Based on this experiment, we conclude that 16-20 hours post-infection is the optimal time at  
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which to harvest the cells, as this is the time period during which the maximum signal of 
particulate CA is reached. 
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Figure 2-5.  A time-course fate-of-capsid experiment in Cf2-LPCX cells infected with EIAV. 
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Figure 2-5 (Continued).  A time-course fate-of-capsid experiment in Cf2-LPCX cells infected with EIAV. 
VSV-G-pseudotyped wt EIAV virions or virions lacking envelope glycoproteins (Env-) were incubated at 37°C with 
Cf2-LPCX cells for 4 h, at which point the cells were washed and the infection was allowed to proceed for variable 
lengths of time.  Following lysis of the target cells, the cytoplasmic lysates were separated over a 50% sucrose 
cushion into supernatant (SN) and particulate (Pellet) fractions.  (A) The fractions were analyzed by Western 
blotting, using polyclonal anti-EIAV serum.  The particulate fraction of the Env- virions was analyzed and blotted 
separately from that of the VSV-G-pseudotyped virions.  A single film was used for both Pellet and SN fractions of 
the wt virions and was exposed for 15-30 seconds.  The film used for the Env- virions was exposed for 2 minutes in 
order to see the band signal. (B) The intensity of each band in the Pellet and SN fractions was estimated using band 
intensity measurements derived from exposed films.  The relative intensity of each band was plotted in Excel to give 
curves showing the increase/decay of signal in the Pellet fraction (blue line) or the SN fraction (maroon line).  An 
exponential curve was fit to time points 16-32 h post-infection for the pellet fraction (cyan dashed line) and the half-
life calculated from the equation of the curve.  A line was fit to time points 12-28 h post-infection for the 
supernatant fraction (orange dashed line) and the half-life calculated from the line equation. 
 
 
To investigate effects of the CA mutations on uncoating, Cf2-LPCX cells were infected for 16 
hours with either wt EIAV or the various mutants.  Infection was allowed to proceed for 4 h, 
followed by a wash, and then continued to 16 h, at which time cells were lysed and treated as 
described above.  Figure 2-6 shows two representative experiments.  Very little cytosolic p26 CA  
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protein was observed in the fractions from cells incubated with the non-enveloped control virus 
(Env-).  Any slight differences in the amount of particulate CA in the pellet fraction of wt EIAV 
versus the CA mutants were not repeatable between experiments.  We conclude, therefore, that 
the introduction of these CA changes does not affect the recovery of particulate CA and that 
defects in uncoating do not explain the severely abrogated infectivity of some of the CA mutants. 
 
Env- Wt N83R R84D L87M N89A N89E L92R V93A M102A E115A E119A
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B
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Figure 2-6.  Fate of the capsid in Cf2-LPCX cells infected with EIAV CA mutants. 
VSV-G-pseudotyped wt and mutant EIAV virions were incubated with Cf2-LPCX cells at 37°C for 4 h, 
washed, and then incubated with fresh media until 16 h post-infection.  As a control, Env- virions were 
included.  The separation of cell lysates into particulate (Pellet) and soluble (SN) fractions, and the blotting of 
each fraction, were done as described for Fig. 2-5.  PVDF membranes containing either the Pellet fraction or the 
SN fraction were exposed on the same piece of film, for 15-30 seconds.  (A) and (B) are two independent 
experiments performed in the same way.   
 
Effects of CA changes on EIAV reverse transcription 
To determine whether the CA mutations affected viral cDNA synthesis, we used a TaqMan-
based real-time PCR assay with specific primer and probe combinations, described previously  
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(25) and detailed in Materials and Methods.  Early and late reverse transcripts were analyzed 
after infection of Cf2-LPCX cells with wt EIAV, the EIAV CA mutants, or Env- EIAV.  In a 
control infection, we challenged cells treated with 150 µM AZT with wt EIAV.  Cf2-LPCX cells 
were infected with equal amounts of virus stocks normalized by RT activity. At specific times 
after infection, cells were harvested by trypsinization and total cellular DNA was isolated. The 
presence of early DNA products (minus-strand strong-stop DNA) was analyzed by the 
primer/probe set detailed in Materials and Methods.  The results revealed that all mutants 
produced levels of early RT products similar to those observed for wt EIAV (Fig. 2-7A).  For all 
viruses, the levels of strong-stop DNA increased until about 18 hours post-infection and then 
began to decrease, suggesting that the EIAV CA mutants do not have any defects in early reverse 
transcription. 
We also examined in parallel the levels of late RT DNA production based on amplification of 
the eGFP gene encoded in the pSIN6.1CeGFPW vector, as described in Materials and Methods.  
Genomic DNA was isolated from harvested cells as early as 15 minutes post-infection and as late 
as 36 hours post-infection.  Once again, the EIAV CA mutants produced levels of late RT 
products similar to those observed for wt EIAV (Fig. 2-7B).  Taken together, these data 
demonstrate that the introduction of the CA mutations does not affect viral cDNA synthesis. 
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Figure 2-7.  Levels of early and late reverse transcripts in infected Cf2-LPCX cells. 
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Figure 2-7 (Continued).  Levels of early and late reverse transcripts in infected Cf2-LPCX cells. 
VSV-G-pseudotyped EIAV wt or mutant viruses were normalized by reverse transcriptase activity and 
incubated with Cf2-LPCX cells.  In addition, Env- EIAV was included as a negative control.  A second negative 
control consisted of wt EIAV infection of cells treated with 150 µM AZT.  At the indicated times post-
infection, cellular DNA was isolated and quantified for each specific DNA species.  Early reverse transcription 
products (strong-stop DNA; Fig. 2-7A) and late reverse transcription products (eGFP; Fig. 2-7B) were 
quantified using a Taqman-based real-time PCR assay.  Data represent the results of a single representative 
experiment.  The color of each CA mutant represents its infectivity in Cf2-LPCX cells (Fig. 2-2).  Blue lines 
correspond to negative controls. 
 
Characterization of nuclear viral DNA. 
Translocation of retroviral DNA from the cytoplasm to the nucleus allows the formation of 2-
LTR circles within the nucleus of the infected cell, and thus the amount of 2-LTR circles reflects 
the efficiency of this translocation (2, 10, 52, 57, 66).  To determine whether the EIAV CA 
changes affected this stage of the viral lifecycle, we measured 2-LTR circular DNA species 
using a SYBR Green-based quantitative real-time PCR assay with the primer set detailed in  
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Materials and Methods.  These primers span the junction of the 5’LTR and 3’LTR that is created 
during 2-LTR circle formation, resulting in an amplicon that is approximately 860 nucleotides 
long.  The results of this assay are summarized in Figure 2-8A.  Genomic DNA from wt EIAV 
and EIAV CA mutants representing three different phenotypes (wt infectivity, infectivity slightly 
higher than wt, and severely abrogated infectivity) was assayed for 2-LTR circle production at 
12, 18, 24 and 36 hours post-infection.  In addition, the negative controls of wild-type EIAV with 
AZT-treated cells, EIAV mutant N89A with AZT-treated cells, and Env- wt EIAV were 
included.  EIAV mutants N83R, L87M, N89A and N89E exhibited 2-LTR circle production at 
levels similar to those of wt EIAV.  These four mutants also exhibited infectivity at levels close 
to or slightly higher than wt EIAV.  Conversely, EIAV mutants R84D, M102A and E119A 
exhibited a significant decrease in 2-LTR circle production as compared to wt EIAV.  The 
amounts of 2-LTR circles produced by these three mutants were similar to the amounts produced 
in the AZT-treated cells and Env- virus controls, which likely represent background in the PCR 
assay.  Therefore, it appears that mutants R84D, M10A and E119A are severely compromised in 
2-LTR circle production.  This may indicate that the loss of infectivity observed with these 
mutants is due to a defect in the ability of these mutants to translocate retroviral DNA from the 
cytoplasm to the nucleus. 
The first step of integration is 3’ processing, in which integrase mediates the hydrolysis of 
GT dinucleotides to create reactive, recessed CAOH-3’ ends (9).  This 3’-processing makes the 
viral DNA vulnerable to autointegration.  Autointegration occurs when these reactive ends attack 
sites within the viral DNA, resulting in nonproductive deletion or inversion circles (16, 31, 34, 
38, 58).  Autointegration products are heterogeneous in size, and when amplified by PCR and 
run on an agarose gel will result in DNA smear (32).  In order to verify that autointegration was  
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not occurring with the EIAV CA mutants, the DNA from the PCR reactions used to amplify the 
2-LTR junction was run on an agarose gel (Fig. 2-8B).  For all mutants tested, a distinct band of 
the correct size (860 nt) was observed, indicating that there was no autointegration. 
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Figure 2-8.  Levels of 2-LTR circles in Cf2-LPCX cells. 
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Figure 2-8 (Continued).  Levels of 2-LTR circles in Cf2-LPCX cells. 
(A) VSV-G-pseudotyped wt EIAV or mutant viruses were normalized by reverse transcriptase activity and 
incubated with Cf2-LPCX cells.  In addition, Env- EIAV and wt EIAV infection of AZT-treated cells (150 µM 
AZT) were included as negative controls.  At the indicated times, genomic DNA was isolated and quantified for 
EIAV 2-LTR circles using a quantitative SYBR Green-based real-time PCR assay.  (B) The 860 nt fragment 
created during the PCR for 2-LTR circles.  DNA molecular weight standards are marked in the leftmost lane. 
 
 
Persistent EIAV viral DNA in Cf2-LPCX cells infected with EIAV CA mutants 
 
To complete the comparative analysis of viral DNA production by the EIAV CA mutants, we 
next evaluated the presence of persistent viral DNA in Cf2-LPCX cells at two weeks post-
infection.  Monitoring the presence of viral DNA at this lengthy time period post-infection 
allows inference of the amount of integrated provirus, as transient DNA forms that are not 
integrated (e.g. 2-LTR circles) should be lost over time.  These data are summarized in Figure 2-
9.  As expected, those mutants which exhibited very low 2-LTR circle production (R84D, 
M102A, and E119A) also showed very low levels of persistent viral DNA, comparable to 
amounts of viral DNA in the negative controls (infection with nonenveloped virus or after AZT 
treatment) (Fig. 2-9A).  These results are consistent with those obtained in the 2-LTR circle 
assay, suggesting that the R84D, M102A and E119A CA mutants are inefficiently imported into 
the nucleus of infected cells.  All other CA mutants showed levels of persistent viral DNA  
 
62 
 
similar to wt EIAV virus.  Interestingly, the three mutants that were more infectious than wt 
EIAV (L87M, N89A and N89E) did not consistently demonstrate an increased amount of 
persistent vDNA.  To determine that the increase in infectivity seen with these mutants 48 h 
post-infection was not due to GFP expression from a transient DNA species lost over the 
following two weeks, cells from these mutants were subjected to FACS at the 2 week post-
infection point before genomic DNA was extracted.  Figure 2-9B shows an example of the FACS 
data.  The relative increase in GFP-positive cells for mutants L87M and N89A at 2 weeks post-
infection was similar to that seen at 48 h post-infection.  As these mutants behaved similarly to 
wt EIAV in all other infection steps surveyed, our assays may not be sufficiently sensitive to 
detect the basis for the observed increase in infectivity.   
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 Figure 2-9.  The presence of persistent viral DNA in Cf2-LPCX cells 2 weeks post-infection. 
VSV-G-pseudotyped EIAV wild-type or mutant viruses were normalized by RT activity and incubated with Cf2-
LPCX cells.  Env- EIAV was included as a negative control.  As an additional control, 150 µM AZT was added to 
cells incubated with some of the viruses.  Infection was allowed to proceed for 2 weeks.  Cells were continuously 
split throughout this time period as they reached confluency.  (A) At the end of 2 weeks, genomic DNA was 
isolated.  The presence of persistent viral DNA was assayed using a Taqman-based quantitative real-time PCR assay 
and the primer/probe set described in Fig. 2-7B, which amplifies a fragment from the eGFP gene. (B) FACS profiles 
of wt. EIAV and mutants L87M and N89A.  The top row contains profiles from cells 48 h after infection.  The 
profiles in the bottom row are from cells 2 weeks post-infection, at which time genomic DNA was harvested and 
real-time PCR used to detect the presence of viral DNA (see A above).  Blue numbers within each window indicate 
the percentage of GFP-positive cells.  Purple numbers indicate the mean fluorescence intensity values. 
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Discussion 
 
In this study, we have created a panel of EIAV CA mutants and attempted to ascertain what 
effects the introduced changes have on the early stages of EIAV infectivity.  We have 
determined that the introduction of single amino-acid residue changes in and around EIAV’s 
proline-rich loop can dramatically alter infectivity.  Three mutants in this study exhibited a 
severe decrease in viral infectivity that appears to occur during the step of nuclear import of the 
pre-integration complex.  Three other mutants exhibited infectivity that was slightly better than 
that of wt EIAV, although no significant differences from the wt virus were detected in the early 
post-entry steps of infection (summarized in Table 2-1).  
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Mutant CL VLPs EM Cf2-
LPCX
Cf2-
TRIM5αRh
Fate of 
CA
Early [x107]
(12 h)
Late [x105 ]
(12 h)
2-LTR 
(24 h)
vDNA
(2 wk)
Wt ++ ++ + ++ - + 1.3 2.2 5.7 x 107 324
G42S + + - -
N83R ++ ++ + + - + 75.7 25.9 1.7 x 107 315
R84D ++ ++ + - - + 28.5 4.3 186 17
H85D + + - -
L87M + + + +++ ++ + 1.8 0.83 5 x 107 154
N89A ++ ++ + +++ ++ + 1.8 5.9 7.3 x 106 293
N89E ++ ++ + +++ ++ + 1.4 0.76 3.7 x 105 473
L92R + ++ + + - + 1.6 0.76
V93A + + + + - + 0.59 1.1
G98E - - - -
M102A ++ ++ + - - + 5.3 1.4 241 14
E115A ++ + + + - + 44.4 15.7
Q117A - - - -
E119A + ++ + - - + 48.8 99.5 1174 21
 
   
Table 2-1.  A summary of the effects of the EIAV CA changes.  CL:  expression/processing in cell lysates.  
VLPs:  production of virus-like particles.   EM:  production of conical cores viewed using thin-section electron 
microscopy.   Cf2-LPCX, Cf2-TRIM5αRh:  infectivity in these cell types measured by GFP positivity.  Fate of 
CA:  uncoating as measured in the fate-of-capsid assay.  Early:  production of early reverse transcripts measured 
by qPCR 12 h post-infection.  Late:  production of late reverse transcripts measured by qPCR 12 h post-
infection.  2-LTR:  production of 2-LTR circles measured by qPCR 24 h post-infection.  vDNA:  persistent 
proviral DNA measured by qPCR 2 weeks post-infection. 
 
 
When the EIAV CA mutants were used to infect either canine-derived Cf2-LPCX cells or 
equine ED cells, we observed phenotypes that we classified into three groups:  mutants that were 
defective (0-15% relative infectivity at highest multiplicity of infection), mutants exhibited 
infectivity levels 30-75% of that of wt EIAV, and those that were slightly more infectious than  
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wt virus.  The severe infectivity defects of several mutants could be explained either by poor Gag 
polyprotein expression (H85D, G98E, Q117A) or poor Gag precursor processing (G42S).  These 
mutants may have altered conformations due to the changes in the proline-rich CA loop.  All of 
the remaining mutants surveyed by thin-section electron microscopy exhibited typical cone-
shaped core morphology.  The incidence of cores with aberrant shapes was similar for these 
mutants and wt EIAV, indicating that introduction of most of the changes in the CA proline-rich 
loop does not affect viral core morphology. 
Application of the fate-of-capsid assay allowed measurement of levels of particulate CA 
in cells infected with CA mutants, providing a window into the uncoating process.  A fate-of-
capsid time course experiment determined the optimal time at which to harvest the cells post-
infection and also provided information about the rate of conversion of particulate CA to soluble 
CA, i.e. the rate of EIAV uncoating.  Under the conditions of our assay, by 20 h post-infection, 
viral entry has diminished.  This allows measurement of the decay constant for EIAV uncoating.  
The implication of this result is that, even at 36 h post-infection, long after nuclear import of pre-
integration complexes, a small percentage of capsids have not yet uncoated.  Whether these 
capsids or partially uncoated capsids are transported into the nucleus is unclear, but the persistent 
presence of the CA helps to explain its role in nuclear import.   
Three EIAV CA mutants (R84D, M102A and E119A) exhibited severe defects in 
infectivity despite levels of expression, Gag processing and virion production that were generally 
comparable to those of wt EIAV.  Only E119A exhibited a lower level of expression than wt 
EIAV in the cells, but released virus efficiently.  When these EIAV CA mutants were used to 
infect cells, we did not observe significant differences between the mutants and wt EIAV, either 
in the amount of particulate CA present or in the rate of conversion to soluble CA.  To look for  
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possible defects in reverse transcription, we used quantitative real-time PCR to measure levels of 
both early and late reverse transcripts at various time points after infection.  All mutants tested, 
regardless of their infectivity phenotypes, produced similar levels of early and late reverse 
transcripts at similar rates.  The combined results of fate-of-capsid experiments and real-time 
PCR suggest that the infectivity defects we observed are not due to problems with uncoating or 
reverse transcription. 
The 2-LTR circular form of DNA is thought to be a reliable indicator of transport of 
retroviral PICs from the cytoplasm to the nucleus (2, 10, 52, 57, 66).  In this study, we observed 
that the three replication-defective mutants (R84D, M102A and E119A) exhibited lower 
production of 2-LTR circles.  In addition, an experiment to measure the amount of viral DNA 
present two weeks post-infection (indicative of integrated provirus) showed a severe decrease in 
the amount of viral DNA present.  Taken together, these data suggest a defect in the step of 
transport of the EIAV PIC to the nucleus.     
Previous studies have found HIV-1 CA mutations that appear to complete uncoating and 
reverse transcription normally but are defective in 2-LTR circle production (13, 25, 44).  
Because the machinery required for nonhomologous end-joining (required for 2-LTR circle 
formation) is located in the nucleus (20), a defect that occurs after reverse transcription but prior 
to nuclear entry of the PIC manifests itself in lower 2-LTR circle production and is associated 
with lower amounts of integrated provirus.  Recently, some HIV-1 CA mutants that are defective 
for 2-LTR circle production have been shown to be unable to interact with certain host nuclear 
import factors.  For example, the N74D CA mutant affects HIV-1 sensitivity to TNPO3 
knockdown, and HIV-1 chimera viruses that contain murine leukemia virus CA protein exhibit 
differential sensitivity to knockdown of Nup153 (1, 5, 29, 44, 56).  
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Although we have determined the viral lifecycle step that is defective in these EIAV CA 
mutants, further studies will be required to determine how these mutations affect nuclear import.  
Thus far, recent studies have shown that EIAV is sensitive to depletion of both TNPO3 and 
NUP153.  In addition, the cargo-binding domain of TNPO3 is critical for the nuclear import of 
divergent lentiviruses.  However, mutational analysis of CA determinants critical to nuclear 
import has focused mainly on the HIV-1 CA.  Here, we have shown that EIAV CA also appears 
to be a critical determinant for nuclear import, which supports the previous HIV-1 studies.  
However, we currently do not have insight as to why these particular CA changes result in this 
defect for EIAV.  Future studies should look at the requirements of host factors critical for HIV-
1 nuclear import and seek to apply these requirements to EIAV.  In addition, further work can be 
done from the viral side to determine the mechanism of import defects for these three mutants. 
Finally, we have identified three amino acid changes to EIAV CA that cause the mutant virus 
to replicate slightly better than wt EIAV.  The mutants L87M, N89A and N89E do not appear 
substantially different from wt virus in terms of 2-LTR circle production or levels of integrated 
provirus.  Because we have not identified a step in the infectivity cycle for these three mutants 
that differs significantly from wt EIAV, it is difficult to account for the increased infectivity they 
display in Cf2-LPCX cells (Fig. 2-2, 2-3).  One possible explanation is that our assays, including 
the fate-of-capsid assay to measure uncoating and real-time PCR assays to measure production 
of early and late transcripts, 2-LTR circles and levels of integrated provirus, are not sensitive 
enough to detect differences between wt EIAV and these three mutants that lead to the observed 
increase in infectivity.  Future experiments on these three mutants should first employ more 
sensitive real-time PCR assays to determine whether there are in fact differences in production of 
any of the DNA species assayed above which could account for their increased replication.  If in  
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fact these CA mutants do not differ from wt virus in any of the steps assayed above, there is the 
unlikely possibility that they preferentially integrate into host genomic sites where they are more 
actively transcribed.  EIAV, like HIV-1, shows a preference for integration into transcription 
units (22, 43).  It may be possible that these three particular CA mutations can in some way 
affect integration site preference in a manner that leads to enhanced GFP expression.  
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The retroviral capsid (CA) protein plays a role in several early steps of the viral life cycle.  
Several studies have addressed the role of CA during the poorly-defined uncoating step, which 
occurs shortly after the viral core enters the target cell cytoplasm.  Lentiviruses like HIV-1 and 
EIAV contain a conical core within the lipid membrane of the virion.  This core is composed of 
CA protein hexamers that form a hexagonal structure termed a fullerene cone (5, 10-12, 15, 21).  
In HIV-1, proper stability of this conical core has been shown to be critical for infection.  
Forshey et al. introduced point mutations into the HIV-1 CA that altered core stability in either a 
positive or negative direction, as assayed by in vitro experiments.  Any alteration in stability 
impaired infectivity at a step prior to or during reverse transcription (7).  This suggests that there 
is an optimal stability to the incoming core that is critical for the early steps of uncoating and/or 
reverse transcription.  In addition, several groups have attempted to purify native core complexes 
from HIV-1 virions with varying degrees of success (1, 7, 17, 27, 35) .  In most cases, these 
purified complexes were extremely labile and disassembled upon the addition of buffer.  These 
studies suggest that the HIV-1 core complex exists in a state of metastability and that small 
alterations to this stability can have deleterious effects on infectivity. 
The retroviral CA protein has also been shown to be the target of certain cellular factors 
that affect the uncoating process.  TRIM5α is a well-known example of a restriction factor that 
negatively modulates uncoating through its interaction with CA and therefore decreases viral 
infectivity.  TRIM5α targets the incoming capsid and causes an accelerated disassembly of core 
complexes (26, 30).  The deleterious effects of accelerated uncoating and altered capsid stability 
suggest that proper temporal regulation is critical to productive uncoating. 
Cyclophilin A (CypA) is another host cell factor that modulates uncoating through its  
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interaction with HIV-1 CA.  CypA binds the HIV-1 CA N-terminal proline-rich CypA-binding 
loop (8, 9, 13, 24, 32).  This loop is exposed on the surface of the assembled HIV-1 capsid.  
Residues Gly89 and Pro90 are particularly critical for CypA binding (3, 29, 34, 39).  Disruption 
of CypA-CA binding, whether through changes in amino acid residues or the addition of the 
CypA-CA binding inhibitor cyclosporine A (CsA), results in an infection block after entry but 
prior to reverse transcription; therefore the CypA-CA interaction appears to be involved in 
modulation of uncoating.  Li et al. have demonstrated that disruption of CypA-CA binding 
causes changes in the levels of cytosolic, particulate CA.  The amount of particulate CA 
recovered from target cell cytosol is correlated to viral infectivity, with lower amounts of 
particulate CA being recovered from CA mutants that are poorly infectious.  However, 
disruption of the CypA-CA interaction can cause different phenotypes depending on target cell 
type (22). 
More recent studies have shown that the role of CA does not end at the uncoating step.  
Lentiviruses are able to infect nondividing cells such as macrophages and quiescent T cells.  This 
suggests that the preintegration complex (PIC) must be actively transported into the nucleus.  
The key viral determinant for nuclear import was recently mapped to CA (36-38).  Recent 
genome-wide siRNA screens have identified host nuclear import factors that are critical for HIV-
1 infectivity, including nuclear pore complex components NUP153, NUP358 and NUP155 and 
the nuclear import protein transportin 3 (TNPO3) (2, 18, 23, 25, 28, 33, 40).  The requirements 
for TNPO3 and NUP153 have both been shown to map to CA, and knockdown of either impairs 
lentiviral infection at the nuclear import step. 
The CA protein of EIAV is quite similar to that of HIV-1.  The two proteins share 30%  
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sequence identity and significant structural similarities (9, 15).  Although it has been difficult to 
purify HIV-1 cores, EIAV cores may be prepared fairly easily from detergent-stripped virions, 
suggesting that the EIAV core may be more stable than that of HIV-1 [(19, 27), Appendix].  In 
addition, EIAV also has a proline-rich loop located between helices 4 and 5 of the N-terminal 
domain.  This loop is presumed to be exposed on the surface of the assembled EIAV CA.  Due to 
the similarities between the two CA proteins and the presumed greater stability of EIAV CA, we 
hypothesized that EIAV CA would be an attractive candidate with which to study the effects of 
CA changes on lentiviral infectivity.  In particular, we hypothesized that introducing changes 
into EIAV’s proline-rich loop would yield interesting phenotypes and that effects of the CA 
mutations would manifest themselves at the uncoating step.  Similar amino acid changes in that 
region of HIV-1 CA have provided insights into HIV-1 infectivity and the uncoating process in 
particular.  In this study, we have introduced amino acid changes in and around EIAV’s CA helix 
4-5 proline-rich loop and then followed the early infection steps of viruses containing these 
changes.  Based on the results of this study, we have concluded that alterations in this region of 
EIAV CA can dramatically alter viral infectivity; however, infection is blocked at the nuclear 
import step and not at uncoating. 
Several of the amino acid substitution mutations resulted in defects in cellular expression 
or Gag processing.  These defects were usually correlated with extremely low levels of 
infectivity in Cf2-LPCX cells.  However, three mutants that exhibited normal expression and 
Gag processing also had severely abrogated infectivity (R84D, M102A, E119A).  Interestingly, 
three other amino acid changes resulted in viruses that were more infectious than wild-type (wt) 
EIAV in Cf2-LPCX cells (L87M, N89A, N89E).  All mutants appeared to form morphologically  
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normal cores at levels similar to wild-type EIAV, suggesting that these amino acid changes did 
not affect core morphology. 
Based on this preliminary data, we found the CA changes created viruses that expressed 
one of three infectivity phenotypes in Cf2-LPCX cells:  poorly infectious, slightly more 
infectious than wt EIAV, or infectious at a level similar to wt.  Since horses are the natural host 
of EIAV, we also wished to test infectivity in an equine cell line.  Overall, a very similar pattern 
was observed in infection of equine dermal (ED) fibroblasts.  Those CA mutants that were 
defective in Cf2-LPCX cells were also defective ED cells, while those that were similar to wt 
EIAV in Cf2-LPCX cells were also similar to wt EIAV in ED cells.  Of the three mutants that 
exhibited better infectivity than wt in Cf2-LPCX cells, two of them were also more infectious 
than wt in ED cells.  Finally, we also wished to test the mutants for sensitivity to rhesus 
TRIM5α, a potent restrictor of EIAV infection.  All CA mutants tested were restricted by rhesus 
TRIM5α at levels comparable to the restriction of wt EIAV, with the exception of the three 
mutants that were more infectious than wt in Cf2-LPCX cells.  These three mutants were also 
less sensitive to the restricting effects of rhesus TRIM5α. 
We had hypothesized that these CA changes might affect viral uncoating, as similar 
amino acid changes in the HIV-1 CypA-binding loop have been shown have effects on uncoating 
that are deleterious to infectivity (7, 22).  To test this hypothesis, we used the fate-of-capsid 
assay to monitor the conversion of particulate CA (representative of intact viral cores) to soluble 
CA (representative of disassembled cores).  Overall, we saw no significant deviations from the 
wt EIAV uncoating pattern for any of these CA mutants.  Data examining levels of early and late 
reverse transcripts further supported this result.  Levels of early and late reverse transcripts were  
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close to that of wt EIAV for all CA mutants tested. 
Thus far the three defective mutants and the three mutants with increased infectivity 
behaved similarly to wt EIAV in the early steps of uncoating and reverse transcription.  Due to 
recent studies implicating CA in nuclear import, we hypothesized the CA changes could affect 
this step and therefore account for differences in infectivity.  For the defective mutants R84D, 
M102A and E119A, this was observed.  These three mutants exhibited decreased production of 
2-LTR circles and also showed very low levels of persistent viral DNA (representative of 
integrated provirus) two weeks post-infection.  As the formation of 2-LTR circles requires 
nuclear DNA repair enzymes, the decreased amount of 2-LTR circles suggests that the PIC is not 
entering the nucleus, which in turn leads to reduced amounts of integrated proviral DNA. 
TNPO3 has recently been identified as a cellular host factor involved in nuclear import of 
HIV-1.  Knockdown of TNPO3 in HIV-1-infected cells reduces the amount of 2-LTR circles.  
However, knockdown has no effect on the amount of 2-LTR circles in cells infected with murine 
leukemia virus (MLV) (4, 6).  As a gammaretrovirus, MLV requires breakdown of the nuclear 
envelope during mitosis to access the nucleus and is not actively transported into the nucleus 
through the nuclear pore channel (NPC) like lentiviruses.  TNPO3 is a member of the 
karyopherin β protein family that imports serine/arginine-rich splicing factors (SR proteins) into 
the nucleus (16).  TNPO3 has three protein domains:  an amino-terminal Ran-GTP binding 
domain, a central nuclear pore channel binding domain, and a carboxy-terminal cargo binding 
domain (31).  Logue et al. have shown that the cargo-binding domain is required for HIV-1 
nuclear import.  In addition, they have demonstrated that several lentiviruses, including 
SIVMAC239 and EIAV, are also dependent on TNPO3 and its cargo-binding domain for nuclear  
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import (23). 
Another factor required for nuclear import of HIV-1 is the NPC component NUP153.  
Matreyek et al. have demonstrated that the requirement for NUP153 also maps to HIV-1 CA.  
NUP153 knockdown results in decreased 2-LTR circle production.  Replacing HIV-1 CA with 
MLV CA rendered the chimeric virus insensitive to NUP153 depletion.  In addition, NUP153 is 
required for infection with lentiviruses SIVMAC, SIVAGMTan, SIVAGMSab, HIV-2ROD and EIAV 
(25). 
The HIV-1 CA mutant N74D does not require TNPO3 or NUP153 for nuclear import and 
can infect nondividing cells.  The N74D mutant was first identified in a selection for HIV-1 
variants that were resistant to the dominant-negative restriction factor mCPSF6-358 (20).  
mCPSF6-358 is a fragment of CPSF6, a cellular polyadenylation factor.  It blocks nuclear import 
of HIV-1, HIV-2 and SIV.  Expression of mCPSF6-358 leads to decreased 2-LTR circle 
production in infected cells.  The HIV-1 CA mutant N74D is resistant to mCPSF6-358.  Lee et 
al. have demonstrated that CPSF6-358 binds wt HIV-1 CA-NC complexes more efficiently than 
it binds HIV-1 N74D CA-NC complexes (20).  mCPSF6-358 accumulates in the cytoplasm, and 
Lee et al. speculate that the interaction of mCPSF6-358 with CA could block interactions with 
critical host nuclear import factors like TNPO3.  
Although N74D is insensitive to both TNPO3 and NUP153 knockdown and to the 
negative effects of mCPSF6-358, interpretation of results obtained using this mutant can be 
complicated due to HIV-1 CA binding CypA.  The N74D mutation increases dependence on 
CypA, and CsA treatment of cells blocks N74D infection (2).  However, adding the  
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compensatory mutation G89V, which creates a CA that cannot bind CypA (N74D/G89V), 
renders the double mutant insensitive to CsA.  In addition, the N74D mutant cannot infect 
macrophages due to a block at reverse transcription (2).  Finally, HIV-1 CA mutants A92E and 
G94D, which exhibit a cell-type-specific CypA requirement, became insensitive to NUP153 
depletion upon CsA treatment (25).  CypA-CA binding and its role in HIV-1 nuclear import 
appears to be a complicated issue that can be affected by parameters such as CsA treatment, cell 
type, and amino acid changes.  
Thus far, research has shown that EIAV infection, like HIV-1 infection, is abrogated by 
knockdown of TNPO3 or NUP153, suggesting that EIAV’s requirement for nuclear import 
factors is similar to that of HIV-1.   As EIAV does not bind CypA, EIAV sensitivity to nuclear 
import factor depletion is more straightforward, and requirements for particular proteins are not 
contingent upon CypA binding.  Therefore, EIAV is an attractive virus to use in further studies 
of the role of CA in nuclear import and host proteins required for it.  Current research has 
focused on EIAV and nuclear import machinery very broadly, only showing that EIAV is 
sensitive to depletion of TNPO3 and NUP153.  An EIAV CA mutation that renders the virus 
insensitive to knockdown of either of these factors (analogous to HIV-1 N74D) has not yet been 
identified.  However, this study has identified three EIAV CA mutants that are defective in 
nuclear import.  Further studies of these particular mutants should attempt to determine the 
reason for this defect.  An examination of the position of the three mutants within the loop region 
suggests a possible explanation (Fig. 3-1).  Each mutated residue (red) is located near a proline 
residue (ochre).  In addition, the amino acid substitutions introduced create charge changes 
which may disrupt critical acidic-basic interactions with nearby side chains (red and blue),  
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thereby changing the conformation of the loop. 
 
Figure 3-1.  The positions within the proline-rich loop of the three amino acid substitutions that cause 
nuclear import defects.  Red:  substituted amino acid residues.  Ochre:  proline residues.  Blue:  unchanged 
amino acid residues whose side chains may interact with those of the substituted residues in wt EIAV. 
   
In addition, ongoing studies examining the requirements of host factors critical for HIV-1 
nuclear import should include EIAV.  Due to the absence of CypA, EIAV CA may yield clearer 
data relating to questions about host factor-CA interaction and sensitivity to host factor 
knockdown.  In addition, the natural host cell type of EIAV infection is the quiescent 
macrophage, and the ability of EIAV CA mutants to infect this cell type should give a clear 
indication of the effects of CA changes on  infection of nondividing cells and therefore  
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provide some insight into effects on nuclear import. 
Unfortunately, we were unable to observe any differences between wt EIAV and the CA 
mutants L87M, N89A and N89E, all of which were more infectious than wt in Cf2-LPCX cells.  
These mutants did not exhibit any significant differences in uncoating as measured by the fate-
of-capsid assay.  They also did not produce significantly different levels of early or late reverse 
transcripts or 2-LTR circles.  Finally, the amount of proviral DNA measured two weeks post-
infection was similar to that of wt.  Comparing the FACS data of these mutants from 48 h post-
infection and 2 weeks post-infection shows that the increased GFP positivity persists, suggesting 
that the higher fluorescence observed for these mutants in Cf2-LPCX cells is not due to 
epigenetic GFP expression from some transient DNA species.  Thus far, the experiments in this 
study have not been able to determine why mutants L87M, N89A and N89E appear to be more 
infectious than wild-type EIAV and also less susceptible to restriction by rhesus TRIM5α.  
Careful examination of standard deviation from the mean in Figure 2-2 may show that the 
increase we see in infectivity in Cf2-LPCX cells is in fact negligible; however, the difference in 
TRIM5α susceptibility seems significant.  Purified EIAV cores have been used previously to 
investigate the binding of TRIM5-21R to EIAV CA (19).  Future studies should employ a similar 
binding assay to investigate rhesus TRIM5α binding to the cores of CA mutants L87M, N89A 
and N89E.  Reduced binding may explain the reduced sensitivity to TRIM5α.  The possibility 
also exists that the assays we used to look at uncoating and production of reverse transcripts, 2-
LTR circles and integrated provirus are not sensitive enough to detect small differences that may 
be the basis of the increased infectivity.  Finally, although we have measured persistent viral 
DNA two weeks post-infection, our assay does not actually measure integrated provirus, nor  
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does it give any information about integration sites.  HIV-1 and EIAV preferentially integrate 
into active transcription units.  Although it seems highly unlikely, one possible explanation for 
enhanced GFP expression in mutants L87M, N89A and N89E could be that the introduction of 
these amino acid changes has in some way caused them to integrate into locations where they are 
more highly expressed than wt EIAV.  This can be examined using ligation-mediated PCR (LM-
PCR), which has previously been used to determine the integration profile of wt EIAV (14).  
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Both HIV-1 and EIAV have conical capsids composed of CA protein hexamers which are 
arranged in the mature virion in a hexagonal lattice termed a fullerene cone (2, 4-6, 8, 11).  
Although intact HIV-1 core complexes can be isolated from membrane-stripped viruses and 
purified using sucrose-gradient centrifugation, these isolated cores are typically unstable and 
tend to disassemble spontaneously in buffer (1, 3, 9, 12, 13).  Structural studies of HIV-1 CA 
have therefore typically used synthetic assemblies created from a CA-NC protein fusion (5).  
However, attempts to isolate EIAV core complexes virions have proven more successful.  
Roberts and Oroszlan were able to isolate intact cores from detergent-treated virions, and these 
cores maintained their characteristic cone shape under electron microscopy (12).  More recently, 
Langelier et al. used purified EIAV cores to test binding of a TRIM5-21R protein to authentic 
purified core particles (10). 
Purification of EIAV cores from VLPs.  293T cells were transfected with the pEV53 EIAV vector and supernatant 
was collected 36 hours post-transfection. Virus-like particles (VLPs) were concentrated in the SW28 rotor, 2 h at 
27000 rpm. VLPs representing one T-175 flask were resuspended in 300 µl and layered over a 300 µl 7% sucrose 
cushion, a 300 µl 15% sucrose/1% NP40cushion, and then a 9 ml 30-70% sucrose gradient or a 9 ml 60% sucrose 
cushion.  Samples were centrifuged in the SW41 rotor at 40000 rpm for either 16 h (gradient) or 3 h (cushion). The 
60% sucrose cushion was aspirated and the pellet of purified cores was resuspended in 100 µl of PBS. Cell lysates 
were prepared using a hypotonic lysis buffer and 3X freeze-thaw cycles. Cell lysates were diluted to a final 
concentration of 2 µg/ml. For each sample, 250 µl of cell lysate was added to 12 µl of cores (the amount of purified 
cores added to each sample represents 1/6 of the VLPs harvested from one transfected T-175 flask, e.g. six samples 
= one flask).  Incubations proceeded for a given amount of time at 37ºC. Samples were centrifuged in an SW55 
rotor, 210000xg, for 2 h. The pellet was resuspended in 100 µl SDS buffer and 50 µl were blotted for p26 (each gel 
lane represents ½ total pellet).  Western blotting for p26 CA was done using an anti-EIAV polyclonal serum and a 
HRP-conjugated anti-horse IgG secondary antibody. 
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We have attempted to isolate intact EIAV cores from detergent-treated virions to use in the study 
of the effects of various cell lysates on CA stability.  The protocol used contains slight 
modifications from that used by Langelier et al. (10)  An example of successful core purification 
is shown in Figure A-1.  Intact EIAV VLPs were created by transfecting one T-175 flask with 25 
µg of the EIAV gag-pol vector pEV53.  The VLPs were harvested 36 h post-transfection, 
clarified and concentrated via centrifugation, then resuspended in 300 µl of PBS.  The VLPs 
were layered onto a 300 µl 7% sucrose cushion, which was layered on top of a 300 µl 15% 
sucrose cushion containing 1% NP40.  Underneath the VLPs and sucrose cushions was a 9 ml 
30-70% sucrose gradient.  These cushion-gradients were then centrifuged in a SW41 rotor at 
40,000 rpm for 16 hours.  Following centrifugation, twelve fractions were collected top-down 
from the gradient, and the “pellet” fraction at the bottom of the tube was also resuspended.  Each 
fraction was blotted for CA (p26) (Fig. A-1B) and the refractive index of each fraction was 
measured (Fig. A-1C).  Fractions 8-11 had the correct density, corresponding to the density of 
EIAV cores (1.22-1.26 g/ml).  
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Figure A-1.  Purification of intact EIAV cores from detergent-treated VLPs using a sucrose gradient.  (A) 
Arrangement of the VLPs, detergent cushion and sucrose gradient prior to centrifugation.  (B)  Top-down fractions 
collected post-centrifugation blotted for p26 using anti-EIAV serum and an HRP-conjugated anti-horse IgG 
secondary antibody.  (C) Fraction density measurements collected via refractometer.  Fractions 8-11 have a density 
corresponding to that of EIAV cores. 
Long sequential periods of centrifugation are required to isolate cores from a sucrose gradient. 
This minimizes the yield of intact complexes recovered, most likely because cores disassemble 
under repeated handling, resuspension and centrifugation.  To minimize the centrifugation and 
handling time in the hopes of increasing the yield of intact cores, we attempted to purify cores 
using a fixed-percentage sucrose cushion rather than a gradient, with or without an overlay of 
detergent.  Figure A-2 shows the results of the various percentages of sucrose tested (when a 
detergent overlay was included, the percentage of NP40 remained fixed at 1% in 15% sucrose in 
a volume of 300 µl).  We hoped to determine the optimal percentage of sucrose that would  
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exclude enveloped VLPs from the pellet while still allowing a substantial percentage of the 
membrane-stripped cores to pellet.  We prioritized exclusion of membrane-intact VLPs over 
yield and therefore chose the more stringent 60% sucrose over higher-yield 53% sucrose.  All 
cores used for subsequent experiments were purified over a 60% sucrose cushion. 
50% 53% 56%
60% 65% 70%
- + - + - +
- + - + - +
50 53 56 60 65 70
- + - + - + - + - + - +
SN
Interface
Pellet
+/- 1% NP40 layer
 
Figure A-2.  Separation of enveloped VLPs from non-enveloped cores using a fixed-percentage sucrose 
cushion.  A 60% sucrose cushion allows optimal separation of purified core complexes from enveloped VLPs while 
retaining a good yield of p26 in the pellet.  SN:  a fraction of supernatant taken from the extreme top of the tube 
post-centrifugation.  Interface:  a fraction taken at the meniscus of the detergent layer/sucrose cushion.  
Previous work has shown that HIV-1 CA mutants that undergo rapid uncoating exhibit 
infectivity defects and cellular cofactors that promote rapid core disassembly (e.g. TRIM5α) also 
have negative effects on infectivity.  Therefore, it is possible that the uncoating process may be a  
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passive disassembly of an inherently unstable virion core.  If this is the case, then during 
productive infection cellular cofactors may act temporally to regulate uncoating by promoting 
core stability rather than disassembly.  Our lab is currently investigating the possible role of 
PDZD8 as one such cellular stabilizing factor using HIV-1 CA-NC complexes [Alex Guth, 
unpublished data; (7)].  Thus far, we have seen that incubation of HIV-1 CA-NC complexes in 
cell lysates stabilizes them to a greater extent than incubation in buffer or PBS.  We wished to 
investigate whether these stabilizing effects were applicable to native core complexes.  Two 
types of cell lysates were tested:  lysates from Cf2 cells stably expressing either the empty 
retroviral vector LPCX or stably expressing rhesus TRIM5α.  We hypothesized that the presence 
of rhesus TRIM5α, which restricts EIAV infection and promotes accelerated uncoating of HIV-1 
in vivo, might also affect core stability in vitro.  The effects of incubation of purified cores in 
either of these two cell lysates are summarized in Figure A-3.  Cores were incubated with either 
cell lysate or PBS for as long as 16 hours and were harvested after various lengths of time to 
develop a time course of stability.  After 2 hours of incubation in PBS, the cores ceased to pellet 
during the post-incubation centrifugation, suggesting that they had disassembled.  However, 
cores incubated with either type of cell lysate continued to pellet up to 16 hours after they were 
added to the lysate.  The amount of particulate CA representing intact cores began to decrease at 
some point between 4-8 hours, as measured by Western blotting for p26 CA in the pellet.  The 
presence of rhesus TRIM5α in the cell lysate did not appear to affect stability, suggesting that the 
presence of rhesus TRIM5α in vitro does not abrogate the stabilizing effect of the cell lysate.  
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Figure A-3.  A time course of core stability in PBS, cell lysates, or cell lysates containing TRIM5αRh.  Purified 
cores were incubated for a given amount of time with either PBS or cell lysates at 37°C.  Post-incubation, particulate 
CA protein was pelleted by centrifugation and the pellet resuspended.  Each pellet was Western blotted for p26. 
 
We also wished to test whether the stabilizing effect we observed with the Cf2 cell lysates was 
conserved across different eukaryotic cell types or possibly even prokaryotic cells.  Purified 
cores were incubated with cell lysates prepared from DH5α bacteria, SF9 insect cell lysate,  
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chicken cell lysate, Cf2-LPCX cell lysate, and lysate from equine dermal (ED) cells.  As a 
negative control, cores were also incubated with PBS.  The incubation of cores with lysates 
proceeded for 4 hours.  Figure A-4 shows the stabilizing effects of the various lysates.  It is 
difficult to interpret whether the bacterial lysate stabilized the cores.  To avoid the introduction 
of any detergent into the reaction, which could lead to core disassembly, bacteria were lysed by 
sonication alone and the lysate clarified by centrifugation.  However, several proteins which 
were nonspecifically recognized by the anti-EIAV serum remained in the lysate.  It appears that 
all the remaining eukaryotic cell lysates do stabilize the cores to some extent, and all of them 
stabilize more than PBS. 
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Figure A-4.  Lysates from a variety of eukaryotic cells stabilize purified EIAV cores.  Purified cores were 
incubated for 4 h at 37°C in PBS or various cell lysates.  Following incubation, the reaction was centrifuged to pellet 
intact cores.  The pellet was resuspended and blotted for p26 CA.  Bacteria:  DH5α; insect:  SF9; Cf2-LPCX:  canine 
thymocytes; equine DF:  dermal fibroblasts. 
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Conclusions 
The results obtained with the purified EIAV CA cores corroborate results our lab has obtained 
from experiments investigating the stability of HIV-1 CA-NC complexes.  For both EIAV cores 
and HIV-1 CA-NC assemblies, we see that cell lysates stabilize the CA complexes better than 
PBS, the presence of the restriction factor TRIM5αRh does not affect complex stability, and the 
stabilizing effect is seen with a variety of eukaryotic cell lysates.  Current work in our lab is 
focused on the possible identity of PDZD8 as the protein responsible for this stabilizing effect.  
We are using both purified EIAV cores and HIV-1 CA-NC assemblies in these experiments.  The 
experiments above have shown that EIAV cores can easily be purified and are reliable markers 
of capsid stability for in vitro experiments.  This method of core purification will be useful in any 
study examining the stability of authentic, purified core particles in vitro and also can be used to 
support findings involving the stability of HIV-1 CA-NC complexes.  In addition, purified EIAV 
cores can be used in assays investigating the binding of other proteins to intact EIAV CA in its 
native form, as has previously been described (10).  
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